JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan is a phase 3, randomised interventional study registered as NCT07384377 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 123 participants, started 2026-02-06 and due to reach its primary completion in 2027-11-30. Interventions recorded: JSKN003; Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.. Conditions listed: HER2-positive Colorectal Cancer. Primary outcome: Progressive Free Survive (PFS) assessed by Independent Review Committee. Colorectal eligibility wording from the registry: "* Unresectable locally advanced or distant metastatic BRAFV600E wild-type colorectal cancer diagnosed histologically or cytologically". No results are recorded here; the registry entry is the source.